the fact that no one from Mgt has addressed the fact that Ocrevus is crushing it in most of the large accounts across the board is telling. I think as far as Gilenya goes, the brand has zero idea how to push back against Ocrevus. So they just ignore it. Excellent strategy guys. But wait, we are still gonna increase your quota and shrink your budget just to keep it interesting.
What we have a new competitor in the market nobody told me. They put their head in the sand hoping the numbers will appear.
